Obesity coverage on Peptide News Digest follows the drugs that actually reshape body weight at scale: GLP-1 agonists, GIP/GLP-1 dual and triple agonists, amylin combinations, and the next layer behind them.
Headline reads from 2025 and 2026: SURMOUNT-5 (tirzepatide vs semaglutide head-to-head), ACHIEVE-3 (orforglipron in obesity), REDEFINE-1 (CagriSema), the SELECT cardiovascular outcomes trial in non-diabetic adults with obesity, and a steady stream of real-world evidence showing the gap between trial weight loss and 12-month routine-care outcomes. Adherence and discontinuation are now the most cited weak points in the category.
The other half of obesity coverage is access — payer policy, Medicare and CMS rulings, the compounding economy, telehealth distribution, and the OMA conference circuit. Browse the latest below.
The World Health Organization published its first guidelines on managing obesity in children and in adolescents on October 7, 2026. For children up to age 9, it makes a strong recommendation against weight-loss medicines, based on low-quality evidence. For ages 10 to 19, it conditionally suggests medicines only for teens who have obesity-related complications, such as type 2 diabetes or uncontrolled high blood pressure, and whose weight has not improved after a supervised diet, exercise, and behavior program lasting at least six months; treatment should be given by a specialist team with long-term follow-up. WHO's evidence review found mostly short trials and noted that teens taking GLP-1 drugs or orlistat stopped more often because of side effects.
Kailera Therapeutics said on Wednesday, September 30, 2026 that it has finished enrolling about 4,900 adults in the three-trial KaiNETIC Phase 3 program for ribupatide, a weekly GLP-1/GIP dual agonist licensed from Hengrui, including KaiNETIC-3, which compares ribupatide with semaglutide 2.4 mg in about 1,200 people with a BMI of 35 or higher. Each trial runs 76 weeks with titration up to 10 mg, and topline results are expected in mid-2028. At EASD on October 1, Kailera reported a 51-person Phase 1 study in which ribupatide exposure after injection in the upper arm or thigh was similar to abdominal injection, and early Phase 1 data for the triple agonist HRS-4729 showing 16.0% mean weight loss at week 12 on 12 mg in 10 participants.
Chugai announced on Monday, September 28, 2026 that Roche is discontinuing development of emugrobart (GYM329), a subcutaneous anti-latent myostatin antibody, for obesity after an interim analysis of the Phase 2 GYMINDA study concluded that the trial was unlikely to meet its pre-specified weight-loss objectives. GYMINDA tested emugrobart in combination with GLP-1/GIP receptor agonists in people with obesity or overweight; Chugai said the antibody was well tolerated, with no new safety signals. All rights return to Chugai, which is preparing to resume development in spinal muscular atrophy and considering out-licensing; Roche had already stopped emugrobart development in spinal muscular atrophy and facioscapulohumeral muscular dystrophy in March 2026.
Researchers led by Karen Hvid of Copenhagen University Hospital, Herlev, are presenting at the EASD annual meeting in Milan an analysis of 313,145 adults with a BMI of 25 or higher and no coronary heart disease or diabetes, drawn from the Copenhagen General Population Study and UK Biobank and followed for up to 18 and 15 years. About 44% (Copenhagen) and 48% (UK Biobank) of people with a BMI of 25 to 26.9, who fall below current GLP-1 weight-loss eligibility, had elevated remnant cholesterol, low-grade inflammation, or both. Those with both markers and no drug indication were 41% (Copenhagen) and 47% (UK Biobank) more likely to develop heart disease than people without an indication and with healthy levels, compared with increases of 41% and 35% among people who already qualify for the drugs. The findings are observational, and the authors said clinical trials are needed.
Boehringer Ingelheim and the WHO Foundation announced on Thursday, September 24, 2026 a three-year collaboration, funded by a $5 million contribution from Boehringer, to help health systems in resource-limited settings monitor and care for obesity and related metabolic conditions. The program is meant to support the WHO Acceleration Plan to Stop Obesity (2022-2030) and to bring health and non-health sectors, along with people living with noncommunicable diseases, into policy discussions. The announcement did not name countries or include access to any specific medicine; Boehringer's obesity pipeline includes survodutide, a GLP-1/glucagon receptor agonist licensed from Zealand Pharma.
Swedish drug-delivery company Nanexa announced on the evening of Thursday, September 24, 2026 a global exclusive license and collaboration agreement giving Novo Nordisk rights to use its PharmaShell platform in up to five development programs for peptide-based drugs in obesity, type 2 diabetes, and other cardiometabolic diseases. PharmaShell uses atomic layer deposition to apply an ultra-thin inorganic coating to individual drug particles to control their release, and the companies are targeting monthly and quarterly injection schedules. Nanexa can receive up to €1.165 billion, of which €615 million is an upfront payment plus development and regulatory milestones and the rest is sales milestones, along with low single-digit royalties; Novo will lead development and commercialization. Reuters reported that Nanexa's shares were up about 122% in Stockholm early on Friday, September 25.
Zealand Pharma announced on September 22, 2026 the start of the Phase 3a ZUPREME program for petrelintide, its once-weekly subcutaneous amylin analog partnered with Roche. The three placebo-controlled trials are ZUPREME-3 (about 3,900 people with overweight or obesity and at least one weight-related comorbidity, without type 2 diabetes), ZUPREME-4 (about 600 people with type 2 diabetes), and ZUPREME-5 (about 2,500 people with established cardiovascular disease). Each trial's primary endpoint is percentage change in body weight from baseline to week 64. A Phase 2 trial combining petrelintide with Roche's GLP-1/GIP agonist enicepatide (CT-388) is planned for the second half of 2026.
Viking Therapeutics reported on Tuesday, September 22, 2026 topline results from a double-blind, placebo-controlled maintenance study of VK2735, its dual GLP-1/GIP receptor agonist, in about 180 adults with a BMI of 30 or higher. After 21 weeks of weekly dosing, placebo-adjusted weight loss was 16% to 19% across VK2735 cohorts; an exploratory cohort on 17.5 mg weekly (n=13) reached about 22% weight loss from baseline at week 33. In the 12-week randomized maintenance phase, every-other-week dosing kept up to 97% of mean weight loss and monthly dosing up to 90%, compared with 61% for patients switched to placebo. Viking said gastrointestinal adverse event rates during maintenance were similar to placebo, and it plans a second part of the study to test oral maintenance regimens.
Corbus Pharmaceuticals (NASDAQ: CRBP) enters Sunday September 13, 2026 the final day of the countdown to Monday September 14 at 8:00 a.m. EDT conference call disclosing Phase 1b CANYON-1 topline data for CRB-913 (once-daily oral peripherally-restricted CB1 inverse agonist for obesity). The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults across once-daily doses of 20 mg, 40 mg, and 60 mg (titrated from 20 mg over four weeks) with a 4-week safety follow-up (NCT07310901). Harold Bays MD (investigator) joins Corbus management. Investor focus is on the CB1 inverse agonist class safety-versus-efficacy trade-off: peripheral restriction (approximately 15-fold lower brain penetration than monlunabant in preclinical models) is designed to preserve dose-responsive weight loss while limiting the psychiatric side effects that led to the 2008 withdrawal of Sanofi's Acomplia (rimonabant). Corbus previously reported Phase 1a mean 2.9% placebo-adjusted weight loss by Day 14. Clean tolerability plus dose-responsive weight loss would enable Phase 2 initiation and position CRB-913 as one of the earliest non-incretin oral obesity options alongside Novo Nordisk cagrilintide (amylin), Structure Therapeutics aleniglipron (oral small-molecule GLP-1), and the Roche petrelintide-enicepatide combo Phase 2.
Corbus Pharmaceuticals (NASDAQ: CRBP) enters the weekend before Monday September 14, 2026 at 8:00 a.m. EDT conference call disclosing Phase 1b CANYON-1 topline data for CRB-913 (once-daily oral peripherally-restricted CB1 inverse agonist for obesity). The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults across once-daily doses of 20 mg, 40 mg, and 60 mg (titrated from 20 mg) with a 4-week safety follow-up (NCT07310901). Harold Bays MD (investigator) will join Corbus management on the call. Investor focus is on the CB1 inverse agonist class safety-versus-efficacy trade-off — the peripheral restriction (approximately 15-fold lower brain penetration than monlunabant in preclinical models) is designed to preserve dose-responsive weight loss while limiting the psychiatric side effects that led to the 2008 withdrawal of Sanofi's Acomplia (rimonabant). Clean tolerability plus dose-responsive weight loss would enable Phase 2 initiation and position CRB-913 as a differentiated non-incretin add-on or alternative to the GLP-1 class. Monday's readout is one of the most-watched non-GLP-1 obesity data points on the September calendar.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced Friday September 11, 2026 that the company will host a conference call and webcast Monday September 14 at 8:00 a.m. EDT to discuss topline data from the Phase 1b CANYON-1 trial of CRB-913 (a once-daily orally-administered peripherally-restricted CB1 inverse agonist for obesity). The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults at once-daily doses of 20 mg, 40 mg, and 60 mg with 4-week safety follow-up (NCT07310901). Last patient last visit was reported August 4, 2026. Harold Bays MD (investigator) will join the call as a guest speaker. CRB-913 is designed to remain peripheral (approximately 15-fold lower brain penetration than monlunabant in preclinical models) to preserve weight-loss efficacy while limiting the psychiatric side effects that led to the 2008 withdrawal of Sanofi's Acomplia (rimonabant). The Monday readout is one of the most-watched non-incretin obesity data points on the September calendar. Clean tolerability plus dose-responsive weight loss would enable Phase 2 initiation and position CRB-913 as a differentiated add-on or alternative to the GLP-1 class.
Corbus Pharmaceuticals (NASDAQ: CRBP) continued through Sunday September 6, 2026 the countdown to CANYON-1 Phase 1b topline data for CRB-913 (a once-daily orally-administered peripherally-restricted CB1 inverse agonist for obesity). Last patient last visit was announced August 4, 2026, and topline is expected in September 2026 per company Q2 2026 corporate update — the specific readout date has not been disclosed but the September window narrows with each passing day. The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults at once-daily doses of 20 mg, 40 mg, and 60 mg with 4-week safety follow-up. CRB-913 is engineered to remain peripheral (approximately 15-fold lower brain penetration than monlunabant in preclinical models) to preserve efficacy while limiting the psychiatric side effects that led to withdrawal of Sanofi's Acomplia (rimonabant) in 2008. Investor focus is on the CB1 inverse agonist class safety-versus-efficacy trade-off plus dose-responsive weight loss. Clean data enables Phase 2 initiation and would position CRB-913 as a non-incretin add-on or alternative to the GLP-1 class.
Corbus Pharmaceuticals (NASDAQ: CRBP) continued through Saturday September 5, 2026 the countdown to CANYON-1 Phase 1b topline data for CRB-913 (a once-daily orally-administered peripherally-restricted CB1 inverse agonist for obesity). Last patient last visit was announced August 4, 2026, and topline is expected in September 2026 per company Q2 2026 corporate update. The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults at once-daily doses of 20 mg, 40 mg, and 60 mg with 4-week safety follow-up. CRB-913 is engineered to remain peripheral (approximately 15-fold lower brain penetration than monlunabant in preclinical models) to preserve efficacy while limiting the psychiatric side effects that led to withdrawal of Sanofi's Acomplia (rimonabant) in 2008. The readout is one of the most-watched non-incretin obesity data points on the September calendar. Clean tolerability plus dose-responsive weight loss would enable Phase 2 initiation and set up CRB-913 as a differentiated add-on or alternative to the GLP-1 class.
Corbus Pharmaceuticals (NASDAQ: CRBP) continued through Friday September 4, 2026 the countdown to CANYON-1 Phase 1b topline data for CRB-913 (a once-daily orally-administered peripherally-restricted CB1 inverse agonist for obesity). Last patient last visit was announced August 4, 2026, and topline is expected in September 2026 per company Q2 2026 corporate update. The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults at once-daily doses of 20 mg, 40 mg, and 60 mg with 4-week safety follow-up. CRB-913 is engineered to remain peripheral (approximately 15-fold lower brain penetration than monlunabant in preclinical models) to preserve efficacy while limiting the psychiatric side effects that led to withdrawal of Sanofi's Acomplia (rimonabant) in 2008. The readout is one of the most-watched non-incretin obesity data points on the September calendar. A clean tolerability profile plus dose-responsive weight loss would enable Phase 2 initiation and set up CRB-913 as a differentiated add-on or alternative to the GLP-1 class.
Corbus Pharmaceuticals (NASDAQ: CRBP) continued through Thursday September 3, 2026 the countdown to CANYON-1 Phase 1b topline data for CRB-913 (a once-daily orally-administered peripherally-restricted CB1 inverse agonist for obesity). Last patient last visit was announced August 4, 2026, and topline is expected in September 2026. The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults at once-daily doses of 20 mg, 40 mg, and 60 mg with 4-week safety follow-up. CRB-913 is engineered to remain peripheral (approximately 15-fold lower brain penetration than monlunabant in preclinical models) to preserve efficacy while limiting the psychiatric side effects that led to withdrawal of Sanofi's Acomplia (rimonabant) in 2008. The readout is one of the most-watched non-incretin obesity data points on the September calendar. A clean tolerability profile plus dose-responsive weight loss would enable Phase 2 initiation and set up CRB-913 as a differentiated add-on or alternative to the incretin class.
Ascletis Pharma (HKEX: 1672) continued enrollment through early September 2026 in the two U.S. Phase 1 studies of ASC36 (a once-monthly to once-quarterly subcutaneous amylin receptor peptide agonist for obesity) and ASC36_35FDC (a once-monthly subcutaneous fixed-dose combination of ASC36 plus GLP-1R/GIPR peptide agonist ASC35) initiated August 10, 2026 following FDA IND clearance July 5. In head-to-head diet-induced-obesity rat studies, ASC36 monotherapy demonstrated approximately 91% greater relative body weight reduction versus Zealand-Roche's petrelintide and approximately 32% greater versus Eli Lilly's eloralintide. If the Phase 1 tolerability profile confirms preclinical differentiation, ASC36 would enter the amylin analog Phase 2 field alongside Novo Nordisk's cagrilintide-in-CagriSema, AstraZeneca's AZD6234 (Milan EASD 2026 September 28-October 2 readout), Metsera's MET-233i, and the Roche-Zealand petrelintide-plus-enicepatide combination Phase 2 initiation planned mid-2026.
Corbus Pharmaceuticals (NASDAQ: CRBP) confirmed Tuesday September 1, 2026 that the CANYON-1 Phase 1b topline data readout for CRB-913 (a once-daily orally-administered highly peripherally-restricted CB1 inverse agonist for obesity) remains on track for September 2026, following completion of the last patient last visit announced August 4. The CANYON-1 study is a 16-week double-blind placebo-controlled dose-ranging trial in 240 obese non-diabetic U.S. adults testing once-daily oral doses of 20 mg, 40 mg, and 60 mg versus placebo with dose titration and 4-week safety follow-up. CRB-913 is engineered to remain peripheral (approximately 15-fold lower brain penetration than the CB1 inverse agonist monlunabant in preclinical models) to preserve efficacy while limiting the psychiatric side effects that led to the withdrawal of Sanofi's Acomplia (rimonabant) in 2008. The mechanism is designed to complement or serve as an alternative to GLP-1 receptor agonists, and the CANYON-1 tolerability profile will determine whether Corbus advances CRB-913 into Phase 2 later in 2026.
Hanmi Pharm (KRX: 128940) signed Monday August 24, 2026 an exclusive licensing agreement with Genentech (a member of the Roche Group) for HM17321, a proprietary urocortin-2 (UCN2) analog peptide for obesity. Deal terms: $190 million upfront payment, up to $2.3 billion in development, regulatory, and commercial milestone payments, plus tiered royalties on sales. Territory: Genentech secures global rights excluding South Korea, where Hanmi retains the license. Mechanism: HM17321 selectively activates the corticotropin-releasing factor 2 receptor (CRFR2), a peptide-hormone receptor pathway distinct from the incretin pathway (GLP-1 receptor, GIP receptor) that anchors every currently-approved obesity drug including semaglutide, tirzepatide, orforglipron, and the broader GLP-1 receptor agonist class. Urocortin-2 is a naturally occurring 38-amino-acid peptide of the corticotropin-releasing factor family. Differentiated profile: HM17321 is positioned as a potential first-in-class treatment designed to simultaneously promote weight loss and preserve lean body mass, an important differentiator against the semaglutide-tirzepatide-retatrutide GLP-1 class where roughly 25% of the total weight lost is lean muscle mass. Development pathway: Hanmi received FDA IND clearance to initiate a Phase 1 clinical trial in November 2025. Hanmi is responsible for completing the Phase 1 clinical trial, after which Genentech will take over development starting with Phase 2 clinical trials. The deal represents one of the largest 2026 obesity licensing transactions and adds a substantially different mechanism to Roche's obesity portfolio that also includes CT-388 (dual GIP/GLP-1 agonist from the Carmot Therapeutics acquisition).